PKU HEALTHCARE has obtained the drug registration certificate for Apremilast Tablets
I'm PortAI, I can summarize articles.
PKU HEALTHCARE has obtained the drug registration certificate for Apremilast tablets issued by the National Medical Products Administration, which includes specifications of 10mg and 30mg. Apremilast is a small molecule inhibitor targeting PDE4, primarily used for the treatment of moderate to severe plaque psoriasis, with advantages such as rapid onset, clear efficacy, and high safety
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments